1 duplicate copy in the archive
EFTA Document EFTA01461339
Title Matchefta-efta01461339
Case Filesd-10-EFTA01461339Dept. of JusticeEFTA Document EFTA01461339
Unknown1p
Case File
sd-10-EFTA01461339Dept. of JusticeEFTA Document EFTA01461339
Other
Classification: Public Gilead Sciences (Buy, CP: $82.02, TP: $132.00, GILD.OQ, Robyn Karnauskas) 4Q13 update: light taxes create more leverage for Sovaldi 4Q13 product revenues beat consensus by -$250M led by inventory & Sovaldi Sovaldi 4Q13 sales were $139M vs. $75M consensus. Pure demand was roughly $50M in the quarter. Remainder of sales came from inventory stocking & purchase for clinical trials. On the HIV front, mgmt noted that 1Q14 will be weaker with similar trends to 1Q13. This tr
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01461339
Pages
1
Persons
0
Integrity
Loading document viewer...
Forum Discussions
Advertisement
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, donor-supported, and independent. Donors see no ads.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.